India, Oct. 12 -- Bristol Myers Squibb (BMY) announced positive topline results from the planned interim analysis of the Phase 3 ACTION-1 trial evaluating RYZ101, an investigational radiopharmaceutical therapy developed by its subsidiary RayzeBio, in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS), as assessed by blinded independent central review. Safety findings were consistent with the known safety profile of RYZ101.
GEP-NETs are rare tumors that develop in the gastrointestinal tract or pancreas. Many tumors express somatostatin receptors, which can be targeted by ...